| Stephanie Schell, | |
|
2424 S 90th St Fl 3, West Allis, WI 53227-2455 | |
| (414) 328-8270 | |
| (414) 328-8275 |
| Full Name | Stephanie Schell |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 2424 S 90th St Fl 3, West Allis, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063840650 | NPI | - | NPPES |
| 100055226 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 5563-033 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
Responding to consumers' concerns about the quality of hospital care in their communities, HealthGrades, the nation's leading independent health care ratings organization, today released the first-ever list of America's Top 50 Cities for Hospital Care. The rankings are based on a comprehensive study of patient death and complication rates at the nation's nearly 5,000 hospitals.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type. The findings may guide the search for improved treatments for heart disease.
› Verified 7 days ago
| Entity Name | Ascension Medical Group-southeast Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609881077 PECOS PAC ID: 8628980943 Enrollment ID: O20031104000421 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
Responding to consumers' concerns about the quality of hospital care in their communities, HealthGrades, the nation's leading independent health care ratings organization, today released the first-ever list of America's Top 50 Cities for Hospital Care. The rankings are based on a comprehensive study of patient death and complication rates at the nation's nearly 5,000 hospitals.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type. The findings may guide the search for improved treatments for heart disease.
› Verified 7 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
Responding to consumers' concerns about the quality of hospital care in their communities, HealthGrades, the nation's leading independent health care ratings organization, today released the first-ever list of America's Top 50 Cities for Hospital Care. The rankings are based on a comprehensive study of patient death and complication rates at the nation's nearly 5,000 hospitals.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type. The findings may guide the search for improved treatments for heart disease.
› Verified 7 days ago
| Entity Name | Pulmonary And Critical Care Associates, Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104938331 PECOS PAC ID: 4183695737 Enrollment ID: O20040805000598 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
Responding to consumers' concerns about the quality of hospital care in their communities, HealthGrades, the nation's leading independent health care ratings organization, today released the first-ever list of America's Top 50 Cities for Hospital Care. The rankings are based on a comprehensive study of patient death and complication rates at the nation's nearly 5,000 hospitals.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type. The findings may guide the search for improved treatments for heart disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Schell, 3301 W Forest Home Ave, Milwaukee, WI 53215-2843 Ph: (414) 328-8270 | Stephanie Schell, 2424 S 90th St Fl 3, West Allis, WI 53227-2455 Ph: (414) 328-8270 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
Responding to consumers' concerns about the quality of hospital care in their communities, HealthGrades, the nation's leading independent health care ratings organization, today released the first-ever list of America's Top 50 Cities for Hospital Care. The rankings are based on a comprehensive study of patient death and complication rates at the nation's nearly 5,000 hospitals.
New genetic evidence strengthens the case that one well-known type of cholesterol is a likely suspect in causing heart disease, but also casts further doubt on the causal role played by another type. The findings may guide the search for improved treatments for heart disease.
› Verified 7 days ago
Paul Facchiano, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6609 W Greenfield Ave, West Allis, WI 53214 Phone: 414-257-8500 | |
Michelle Cyr, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2514 S 102nd St Ste 160, West Allis, WI 53227 Phone: 414-255-0300 | |
Autumn D Unrein, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2424 S 90th St Fl 2, West Allis, WI 53227 Phone: 414-328-8777 Fax: 414-328-8110 | |
Katelyn Nieman, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2514 S 102nd St Ste 160, West Allis, WI 53227 Phone: 414-255-0340 Fax: 855-342-0199 | |
Mr. Joseph Kozlosky, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10827 W Lincoln Ave, West Allis, WI 53227 Phone: 414-541-6010 Fax: 414-541-5509 | |
John Thomas Olstad, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1706 S 68th St, West Allis, WI 53214 Phone: 414-667-4800 |